Premium Nahrungsergänzungsmittel | artgerecht

Angioedema Prophylaxis: Prevention of Angioedema

Angioedema prophylaxis includes medicinal and non-medicinal strategies to prevent recurrent episodes of angioedema, especially in hereditary angioedema (HAE).

Regular tips about health Regular tips about health

Things worth knowing about "Angioedema Prophylaxis"

Angioedema prophylaxis includes medicinal and non-medicinal strategies to prevent recurrent episodes of angioedema, especially in hereditary angioedema (HAE).

What is Angioedema Prophylaxis?

Angioedema prophylaxis refers to all preventive measures aimed at reducing the frequency and severity of angioedema attacks or preventing them altogether. Angioedema is a sudden, deep swelling of the skin and mucous membranes, commonly affecting the face, lips, tongue, throat, and extremities. These swellings can be life-threatening, especially when they involve the upper airways. Prophylaxis is therefore a central component of the long-term management of patients with recurrent angioedema.

Types of Angioedema and Relevance of Prophylaxis

Angioedema can arise from several different causes. The most important forms include:

Hereditary Angioedema (HAE): A rare, genetically determined condition caused by a deficiency or dysfunction of the C1-inhibitor protein. Without prophylaxis, attacks can be frequent and severe.
Acquired Angioedema (AAE): Caused by an acquired C1-inhibitor deficiency, often in association with underlying diseases.
Allergic Angioedema: Triggered by allergic reactions to foods, insect stings, or medications.
Drug-induced Angioedema: A well-known side effect of ACE inhibitors used in blood pressure therapy.
Idiopathic Angioedema: Angioedema with no identifiable cause.

Prophylaxis is especially important in hereditary angioedema, where untreated patients face significantly impaired quality of life and an elevated risk of life-threatening laryngeal swelling.

Types of Angioedema Prophylaxis

Long-Term Prophylaxis

Long-term prophylaxis aims to persistently reduce attack frequency in patients with frequent or severe angioedema episodes. The following agents and strategies are used:

C1-Inhibitor Concentrates (C1-INH): Intravenous or subcutaneous administration of plasma-derived or recombinant C1-inhibitor (e.g., conestat alfa). These directly replace the deficient or non-functional protein.
Lanadelumab: A monoclonal antibody that inhibits plasma kallikrein activity, thereby preventing the release of bradykinin. Administered subcutaneously every two to four weeks, lanadelumab has transformed long-term prophylaxis of HAE.
Berotralstat: An orally administered plasma kallikrein inhibitor that reduces the frequency of HAE attacks.
Antifibrinolytic agents (e.g., tranexamic acid): Used particularly in children or when other therapies are unavailable or unsuitable.
Attenuated androgens (e.g., danazol): Stimulate hepatic synthesis of C1-inhibitor. Due to significant side effects, their use is now limited to selected cases at low doses. Not suitable for children, pregnant women, or breastfeeding mothers.

Short-Term Prophylaxis

Short-term prophylaxis is used before known triggers such as medical or dental procedures, surgery, or other physical or emotional stressors. The goal is to minimize the risk of an attack during this period.

Administration of C1-inhibitor concentrate shortly before the procedure.
Use of attenuated androgens (e.g., danazol) for a limited period before the triggering event.
In certain situations, administration of Fresh Frozen Plasma (FFP) if other preparations are unavailable.

General and Non-Pharmacological Measures

In addition to drug-based prophylaxis, non-pharmacological strategies also play an important role:

Trigger avoidance: Identifying and avoiding individual triggers such as stress, trauma, infections, and certain medications (especially ACE inhibitors and estrogen-containing contraceptives).
Patient education: Informing patients about their condition, the use of emergency medications, and what to do during an acute attack.
Emergency preparedness: Patients with hereditary angioedema should always carry emergency medications (e.g., icatibant, C1-INH concentrate) and be trained in their use.
Regular medical follow-up: To adjust therapy and monitor disease progression.

Diagnosis and Treatment Planning

Before starting prophylaxis, a thorough diagnostic workup is performed. This includes laboratory tests (e.g., C1-inhibitor levels and function, C4 complement), a detailed medical history, and where appropriate, genetic testing. Treatment decisions are made on an individual basis, taking into account attack frequency and severity, patient age, comorbidities, and tolerability of medications. International guidelines from organizations such as the WAO/EAACI and HAEi (Hereditary Angioedema International) form the basis for treatment planning.

References

Maurer M, Magerl M, Ansotegui I et al. - The international WAO/EAACI guideline for the management of hereditary angioedema. Allergy, 2022; 77(7): 1961-1990.
Busse PJ, Christiansen SC - Hereditary Angioedema. New England Journal of Medicine, 2020; 382(12): 1136-1148.
Zanichelli A, Azin GM, Wu MA et al. - Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. Journal of Allergy and Clinical Immunology: In Practice, 2017; 5(5): 1307-1313.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.